Tag: Antimicrobial Resistance Diagnostics Market – Global Antimicrobial Resistance Diagnostics Industry Size

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The challenge of antimicrobial resistance is becoming increasingly critical worldwide, prompting the need for advanced diagnostic tools to effectively detect and manage resistant infections. The antimicrobial resistance diagnostics market is evolving rapidly, driven by technological innovations and rising awareness about the importance of early detection. This overview explores the current market size, growth drivers, segmentation, emerging trends, competitive players, and regional highlights shaping the future of this vital healthcare sector.

Antimicrobial Resistance Diagnostics Market Size and Projected Growth

The antimicrobial resistance diagnostics market has witnessed substantial expansion in recent years. It is expected to grow from $4.41 billion in 2025 to $4.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth has been fueled by the increasing incidence of antibiotic-resistant infections, a strong dependence on traditional culture-based diagnostics, a rise in hospital-acquired infections, heightened awareness of antimicrobial stewardship, and the expansion of clinical microbiology laboratories worldwide. Looking ahead, the market is anticipated to reach $6.23 billion by 2030, with a CAGR of 7.1%. Factors supporting this future growth include advancements in PCR and NGS diagnostic technologies, greater government funding for antimicrobial resistance (AMR) surveillance programs, a rising shift toward rapid diagnostic tests, expansion in pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Key market trends during the forecast period are the growing use of rapid and point-of-care AMR diagnostics, increasing demand for targeted and personalized antimicrobial therapies, enhanced surveillance of drug-resistant pathogens, expanded molecular and genomic diagnostic testing, and stronger hospital infection control and stewardship initiatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Key Factors Fueling Growth in the Antimicrobial Resistance Diagnostics Market

One of the primary drivers of this market is the rising prevalence of drug-resistant infections, which occur when microbes such as bacteria, viruses, fungi, or parasites develop the ability to withstand treatments that were once effective. This resistance complicates standard treatments and makes infections more difficult to control. A significant contributor to this problem is the overuse of antibiotics in agriculture, where low doses are regularly added to animal feed, promoting resistance that can transfer to humans through the food supply. Antimicrobial resistance diagnostics—including rapid genetic testing and culture-based sensitivity assays—are critical in addressing this challenge by enabling early detection of resistant pathogens, guiding precise therapies, and reducing unnecessary use of broad-spectrum antibiotics.

For instance, data released in November 2024 by the UK Health Security Agency (UKHSA) revealed that serious antibiotic-resistant infections in England increased from 58,224 cases in 2022 to about 66,730 in 2023, alongside a 2.4% rise in antibiotic use during the same period. This rising prevalence of resistant infections underscores the urgent need for improved diagnostic solutions, thereby driving growth in the antimicrobial resistance diagnostics market.

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Antimicrobial Resistance Diagnostics Market Global Footprint: Which Region Holds Market Leadership?

Detailed Segmentation of the Antimicrobial Resistance Diagnostics Market

The report categorizes the antimicrobial resistance diagnostics market into multiple key segments to provide a thorough analysis:

1) Product Type: Kits and Reagents; Instruments and Consumables

2) Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), and other pathogens

3) Technology: Microbiology Culture, Immunoassay, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Mass Spectrometry, Rapid and Point of Care, among others

4) End-User: Hospitals and Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical and Biotechnology Companies, and other users

Further sub-segments include specific product types such as DNA and RNA extraction kits, PCR reagents, immunoassay reagents, stains and dyes, culture media, PCR machines, UV-Vis spectrophotometers, NGS systems, microarray scanners, automated liquid handlers, and sample collection tubes and swabs.

Cutting-Edge Innovations Transforming the Antimicrobial Resistance Diagnostics Industry

Leading companies in the antimicrobial resistance diagnostics sector are increasingly focusing on innovative technologies to improve the speed, accuracy, and clinical utility of testing. A significant advancement is the adoption of point-of-care antimicrobial susceptibility testing (AST) systems, which enable near-patient tests to rapidly identify effective antibiotics for infections. This helps clinicians make quicker, more targeted treatment decisions and supports antimicrobial stewardship by reducing unnecessary antibiotic prescriptions.

A notable example is the June 2023 launch of the PA-100 AST System by Sysmex Corporation, a Japan-based diagnostic solutions provider. This point-of-care platform analyzes urine samples, detecting bacterial presence and antibiotic susceptibility in about 30 minutes. The system uses microfluidic single-cell analysis, allows near-patient testing, and automates reporting, thereby facilitating timely and precise clinical decision-making to combat antimicrobial resistance.

Key Market Players Leading the Antimicrobial Resistance Diagnostics Sector

Several prominent companies are shaping the antimicrobial resistance diagnostics market, including:

F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, and Hologic Inc.

Geographical Trends and Market Leadership in the Antimicrobial Resistance Diagnostics Sector

In 2025, North America dominated the antimicrobial resistance diagnostics market, holding the largest regional share. Meanwhile, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market report covers multiple regions, including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive view of global market dynamics.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Antimicrobial Resistance Diagnostics Market By 2030 Based On Its 2026 Value?

The antimicrobial resistance diagnostics market has experienced significant growth in recent years. It is forecast to grow from $4.41 billion in 2025 to $4.74 billion in 2026, at a compound annual growth rate (CAGR) of 7.5%. The market’s historical expansion can be linked to the rising incidence of antibiotic-resistant infections, the persistent use of traditional culture-based diagnostics, an increase in hospital-acquired infections, greater understanding of antimicrobial stewardship, and the enlargement of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is largely due to advancements in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, a growing embrace of rapid diagnostic tests, an uptick in pharmaceutical and biotechnology research, and the incorporation of data-driven decision support tools. Key trends anticipated within this period involve the increasing adoption of rapid and point-of-care AMR diagnostics, a heightened demand for targeted and personalized antimicrobial therapy, intensified surveillance of drug-resistant pathogens, an expansion of molecular and genomic-based diagnostic testing, and the reinforcement of hospital infection control and stewardship programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Core Factors Are Supporting The Expansion Of The Antimicrobial Resistance Diagnostics Market?

The increasing occurrence of infections resistant to drugs is anticipated to drive the expansion of the antimicrobial resistance diagnostics market in the future. Such infections develop when bacteria, viruses, fungi, or parasites evolve ways to withstand medications that previously worked, rendering standard treatments ineffective and making these infections more challenging to manage. This escalating prevalence of drug-resistant infections stems from the excessive use of antibiotics in agriculture, where small amounts of antimicrobials are regularly incorporated into animal feed, fostering resistance that can then transfer to people via the food chain. Tools for diagnosing antimicrobial resistance, including quick genetic tests and culture-based sensitivity evaluations, are crucial in countering the rising incidence of drug-resistant infections. They achieve this by allowing for the prompt detection of resistant disease-causing agents, informing specific treatment approaches, and lessening the inappropriate use of wide-ranging antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a government body located in the UK, indicated that severe antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023. Concurrently, antibiotic consumption saw an increase to 2.4% in 2023 from 2022. Consequently, the increasing frequency of drug-resistant infections is fueling the expansion of the antimicrobial resistance diagnostics market.

Which Segment Groups Define The Antimicrobial Resistance Diagnostics Market Landscape?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

What Trends Are Influencing The Antimicrobial Resistance Diagnostics Market?

Leading companies within the antimicrobial resistance (AMR) diagnostics market are increasingly focusing on utilizing innovative technologies, such as point-of-care antimicrobial-susceptibility testing (AST) systems, to improve diagnostic speed, accuracy, and the effectiveness of antimicrobial stewardship. Point-of-care antimicrobial-susceptibility testing (AST) refers to quick, patient-side tests that determine which antibiotics are effective against an infection, enabling clinicians to rapidly choose targeted and effective treatments. For example, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, unveiled the PA-100 AST System. This rapid point-of-care AST platform is designed to detect bacterial presence and ascertain antimicrobial susceptibility in urine samples within approximately 30 minutes. The system incorporates microfluidic single-cell analysis, provides near-patient testing capabilities, and automatically reports susceptibility outcomes. Ultimately, the PA-100 AST System enhances clinical decision-making, decreases unnecessary antibiotic prescriptions, and supports the delivery of timely, targeted therapy to combat antimicrobial resistance.

Who Are The Companies Shaping The Antimicrobial Resistance Diagnostics Market Landscape?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Access The Complete Antimicrobial Resistance Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Leads The Antimicrobial Resistance Diagnostics Market By Size?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Antimicrobial Resistance Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Antimicrobial Resistance Diagnostics Market By 2030 Based On Its 2026 Value?

The antimicrobial resistance diagnostics market has experienced significant growth in recent years. It is forecast to grow from $4.41 billion in 2025 to $4.74 billion in 2026, at a compound annual growth rate (CAGR) of 7.5%. The market’s historical expansion can be linked to the rising incidence of antibiotic-resistant infections, the persistent use of traditional culture-based diagnostics, an increase in hospital-acquired infections, greater understanding of antimicrobial stewardship, and the enlargement of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is largely due to advancements in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, a growing embrace of rapid diagnostic tests, an uptick in pharmaceutical and biotechnology research, and the incorporation of data-driven decision support tools. Key trends anticipated within this period involve the increasing adoption of rapid and point-of-care AMR diagnostics, a heightened demand for targeted and personalized antimicrobial therapy, intensified surveillance of drug-resistant pathogens, an expansion of molecular and genomic-based diagnostic testing, and the reinforcement of hospital infection control and stewardship programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Core Factors Are Supporting The Expansion Of The Antimicrobial Resistance Diagnostics Market?

The increasing occurrence of infections resistant to drugs is anticipated to drive the expansion of the antimicrobial resistance diagnostics market in the future. Such infections develop when bacteria, viruses, fungi, or parasites evolve ways to withstand medications that previously worked, rendering standard treatments ineffective and making these infections more challenging to manage. This escalating prevalence of drug-resistant infections stems from the excessive use of antibiotics in agriculture, where small amounts of antimicrobials are regularly incorporated into animal feed, fostering resistance that can then transfer to people via the food chain. Tools for diagnosing antimicrobial resistance, including quick genetic tests and culture-based sensitivity evaluations, are crucial in countering the rising incidence of drug-resistant infections. They achieve this by allowing for the prompt detection of resistant disease-causing agents, informing specific treatment approaches, and lessening the inappropriate use of wide-ranging antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a government body located in the UK, indicated that severe antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023. Concurrently, antibiotic consumption saw an increase to 2.4% in 2023 from 2022. Consequently, the increasing frequency of drug-resistant infections is fueling the expansion of the antimicrobial resistance diagnostics market.

Which Segment Groups Define The Antimicrobial Resistance Diagnostics Market Landscape?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

What Trends Are Influencing The Antimicrobial Resistance Diagnostics Market?

Leading companies within the antimicrobial resistance (AMR) diagnostics market are increasingly focusing on utilizing innovative technologies, such as point-of-care antimicrobial-susceptibility testing (AST) systems, to improve diagnostic speed, accuracy, and the effectiveness of antimicrobial stewardship. Point-of-care antimicrobial-susceptibility testing (AST) refers to quick, patient-side tests that determine which antibiotics are effective against an infection, enabling clinicians to rapidly choose targeted and effective treatments. For example, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, unveiled the PA-100 AST System. This rapid point-of-care AST platform is designed to detect bacterial presence and ascertain antimicrobial susceptibility in urine samples within approximately 30 minutes. The system incorporates microfluidic single-cell analysis, provides near-patient testing capabilities, and automatically reports susceptibility outcomes. Ultimately, the PA-100 AST System enhances clinical decision-making, decreases unnecessary antibiotic prescriptions, and supports the delivery of timely, targeted therapy to combat antimicrobial resistance.

Who Are The Companies Shaping The Antimicrobial Resistance Diagnostics Market Landscape?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Access The Complete Antimicrobial Resistance Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Leads The Antimicrobial Resistance Diagnostics Market By Size?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Antimicrobial Resistance Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Antimicrobial Resistance Diagnostics Market Expected To Scale Between 2026 And 2030?

The antimicrobial resistance diagnostics market has observed substantial growth in recent years. This market is projected to expand from $4.41 billion in 2025 to $4.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. Key drivers for its historical development include the increasing occurrence of antibiotic-resistant infections, the widespread use of conventional culture-based diagnostics, a surge in hospital-acquired infections, greater recognition of antimicrobial stewardship, and the establishment of more clinical microbiology laboratories.

The antimicrobial resistance diagnostics market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $6.23 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is attributable to progress in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, the growing uptake of rapid diagnostic tests, the growth in pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Significant trends expected in this period include the rising adoption of rapid and point-of-care AMR diagnostics, an increasing demand for targeted and personalized antimicrobial therapy, enhanced surveillance of drug-resistant pathogens, the expansion of molecular and genomic-based diagnostic testing, and the strengthening of hospital infection control and stewardship programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Primary Drivers Are Impacting The Antimicrobial Resistance Diagnostics Market Growth?

The increasing occurrence of drug-resistant infections is projected to drive the growth of the antimicrobial resistance diagnostics market in the future. Such infections arise when bacteria, viruses, fungi, or parasites evolve mechanisms to survive exposure to drugs that were previously effective against them, rendering standard therapies ineffective and making infections more difficult to manage. The growing prevalence of drug-resistant infections is attributed to the overuse of antibiotics in agriculture, where low-dose antimicrobials are routinely added to animal feed, fostering resistance that can spread to humans through the food chain. Antimicrobial resistance diagnostics, including rapid genetic assays and culture-based sensitivity tests, are crucial in combating the rising incidence of drug-resistant infections by enabling the early identification of resistant pathogens, guiding targeted treatments, and minimizing the misuse of broad-spectrum antibiotics. For instance, in November 2024, the UK Health Security Agency (UKHSA), a UK-based government agency, reported that the number of serious antibiotic-resistant infections in England increased from 58,224 in 2022 to an estimated 66,730 in 2023, while antibiotic use climbed to 2.4% in 2023 from 2022. Consequently, the rising prevalence of drug-resistant infections is propelling the expansion of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Segmented Across Different Segment Categories?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Shaping Growth In The Antimicrobial Resistance Diagnostics Market?

Major companies within the antimicrobial resistance (AMR) diagnostics market are concentrating on utilizing cutting-edge technologies, such as point-of-care antimicrobial-susceptibility testing (AST) solutions, to improve diagnostic speed, accuracy, and outcomes related to antimicrobial stewardship. Point-of-care antimicrobial-susceptibility testing (AST) refers to swift, patient-side tests that identify which antibiotics will be effective against an infection, thereby assisting clinicians in quickly selecting targeted and successful treatments. For example, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, launched the PA-100 AST System. This point-of-care rapid AST platform is designed to detect bacterial presence and determine antimicrobial susceptibility in urine samples in approximately 30 minutes. The system incorporates microfluidic single-cell analysis, offers near-patient testing, and provides automated reporting of susceptibility results. The PA-100 AST System significantly enhances clinical decision-making, helps reduce unnecessary antibiotic prescriptions, and supports timely, targeted therapy in the fight against antimicrobial resistance.

Which Organizations Play A Role In The Antimicrobial Resistance Diagnostics Market Landscape?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Get The Full Antimicrobial Resistance Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Geographic Region Dominates The Antimicrobial Resistance Diagnostics Market?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antimicrobial Resistance Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Antimicrobial Resistance Diagnostics Market Expected To Change Between 2026 And 2030?

The antimicrobial resistance diagnostics market has demonstrated robust growth in recent years. It is projected to expand from $4.41 billion in 2025 to $4.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth observed in the historical period can be ascribed to the increasing prevalence of antibiotic-resistant infections, the reliance on conventional culture-based diagnostics, a rise in hospital-acquired infections, growing awareness of antimicrobial stewardship, and the expansion of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market size is anticipated to undergo significant expansion in the coming years. This market is projected to reach $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. The expected growth during the forecast period is driven by advancements in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, the rising adoption of rapid diagnostic tests, growth within pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Prominent trends for the forecast period include the increasing uptake of rapid and point-of-care AMR diagnostics, a growing demand for targeted and personalized antimicrobial therapy, enhanced surveillance of drug-resistant pathogens, the expansion of molecular and genomic-based diagnostic testing, and the strengthening of hospital infection control and stewardship programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Major Factors Are Driving The Expansion Of The Antimicrobial Resistance Diagnostics Market?

The growing occurrence of drug-resistant infections is anticipated to drive the expansion of the antimicrobial resistance diagnostics market. These infections develop when bacteria, viruses, fungi, or parasites adapt ways to withstand medications that were once effective, rendering conventional treatments useless and infections more challenging to manage. The increasing spread of drug-resistant infections stems from the excessive use of antibiotics in agriculture, where low-dose antimicrobials are commonly incorporated into animal feed, fostering resistance that can transfer to humans via the food chain. Antimicrobial resistance diagnostics, including rapid genetic assays and culture-based sensitivity tests, are essential in combating the rising incidence of drug-resistant infections. They achieve this by allowing for prompt identification of resistant pathogens, directing precise treatments, and lessening the inappropriate use of broad-spectrum antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a UK-based government agency, stated that the count of serious antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023. Concurrently, antibiotic consumption rose by 2.4% in 2023 compared to 2022. Consequently, the escalating prevalence of drug-resistant infections is a key factor propelling the expansion of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Structured Across Different Segments?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Shaping The Future Of The Antimicrobial Resistance Diagnostics Market?

Companies operating in the **antimicrobial resistance (AMR) diagnostics market** are strategically using innovative technologies, such as **point-of-care antimicrobial-susceptibility testing (AST) technologies**, to enhance diagnostic speed, precision, and the effectiveness of antimicrobial stewardship programs. **Point-of-care antimicrobial-susceptibility testing (AST)** refers to quick tests conducted near the patient that determine which antibiotics are effective against an infection, enabling clinicians to rapidly choose targeted and effective treatments. For example, in **June 2023**, **Sysmex Corporation**, a Japan-based provider of in-vitro diagnostic solutions, launched the **PA-100 AST System**. This platform is a rapid, point-of-care AST system designed to detect bacterial presence and ascertain antimicrobial susceptibility in urine samples within approximately **30 minutes**. The system includes microfluidic single-cell analysis, near-patient testing capabilities, and automated reporting of susceptibility outcomes. The **PA-100 AST System** improves clinical decision-making, helps reduce unnecessary antibiotic prescriptions, and supports timely, targeted therapies to combat antimicrobial resistance.

Which Major Players Dominate The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Read the full antimicrobial resistance diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Antimicrobial Resistance Diagnostics Market?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antimicrobial Resistance Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Antimicrobial Resistance Diagnostics Market Expected To Change Between 2026 And 2030?

The antimicrobial resistance diagnostics market has demonstrated robust growth in recent years. It is projected to expand from $4.41 billion in 2025 to $4.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth observed in the historical period can be ascribed to the increasing prevalence of antibiotic-resistant infections, the reliance on conventional culture-based diagnostics, a rise in hospital-acquired infections, growing awareness of antimicrobial stewardship, and the expansion of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market size is anticipated to undergo significant expansion in the coming years. This market is projected to reach $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. The expected growth during the forecast period is driven by advancements in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, the rising adoption of rapid diagnostic tests, growth within pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Prominent trends for the forecast period include the increasing uptake of rapid and point-of-care AMR diagnostics, a growing demand for targeted and personalized antimicrobial therapy, enhanced surveillance of drug-resistant pathogens, the expansion of molecular and genomic-based diagnostic testing, and the strengthening of hospital infection control and stewardship programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Major Factors Are Driving The Expansion Of The Antimicrobial Resistance Diagnostics Market?

The growing occurrence of drug-resistant infections is anticipated to drive the expansion of the antimicrobial resistance diagnostics market. These infections develop when bacteria, viruses, fungi, or parasites adapt ways to withstand medications that were once effective, rendering conventional treatments useless and infections more challenging to manage. The increasing spread of drug-resistant infections stems from the excessive use of antibiotics in agriculture, where low-dose antimicrobials are commonly incorporated into animal feed, fostering resistance that can transfer to humans via the food chain. Antimicrobial resistance diagnostics, including rapid genetic assays and culture-based sensitivity tests, are essential in combating the rising incidence of drug-resistant infections. They achieve this by allowing for prompt identification of resistant pathogens, directing precise treatments, and lessening the inappropriate use of broad-spectrum antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a UK-based government agency, stated that the count of serious antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023. Concurrently, antibiotic consumption rose by 2.4% in 2023 compared to 2022. Consequently, the escalating prevalence of drug-resistant infections is a key factor propelling the expansion of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Structured Across Different Segments?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Shaping The Future Of The Antimicrobial Resistance Diagnostics Market?

Companies operating in the **antimicrobial resistance (AMR) diagnostics market** are strategically using innovative technologies, such as **point-of-care antimicrobial-susceptibility testing (AST) technologies**, to enhance diagnostic speed, precision, and the effectiveness of antimicrobial stewardship programs. **Point-of-care antimicrobial-susceptibility testing (AST)** refers to quick tests conducted near the patient that determine which antibiotics are effective against an infection, enabling clinicians to rapidly choose targeted and effective treatments. For example, in **June 2023**, **Sysmex Corporation**, a Japan-based provider of in-vitro diagnostic solutions, launched the **PA-100 AST System**. This platform is a rapid, point-of-care AST system designed to detect bacterial presence and ascertain antimicrobial susceptibility in urine samples within approximately **30 minutes**. The system includes microfluidic single-cell analysis, near-patient testing capabilities, and automated reporting of susceptibility outcomes. The **PA-100 AST System** improves clinical decision-making, helps reduce unnecessary antibiotic prescriptions, and supports timely, targeted therapies to combat antimicrobial resistance.

Which Major Players Dominate The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Read the full antimicrobial resistance diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Antimicrobial Resistance Diagnostics Market?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antimicrobial Resistance Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Antimicrobial Resistance Diagnostics Market Expected To Change Between 2026 And 2030?

The antimicrobial resistance diagnostics market has demonstrated robust growth in recent years. It is projected to expand from $4.41 billion in 2025 to $4.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth observed in the historical period can be ascribed to the increasing prevalence of antibiotic-resistant infections, the reliance on conventional culture-based diagnostics, a rise in hospital-acquired infections, growing awareness of antimicrobial stewardship, and the expansion of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market size is anticipated to undergo significant expansion in the coming years. This market is projected to reach $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. The expected growth during the forecast period is driven by advancements in PCR and NGS diagnostic technologies, increased government funding for AMR surveillance programs, the rising adoption of rapid diagnostic tests, growth within pharmaceutical and biotechnology research, and the integration of data-driven decision support tools. Prominent trends for the forecast period include the increasing uptake of rapid and point-of-care AMR diagnostics, a growing demand for targeted and personalized antimicrobial therapy, enhanced surveillance of drug-resistant pathogens, the expansion of molecular and genomic-based diagnostic testing, and the strengthening of hospital infection control and stewardship programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

Which Major Factors Are Driving The Expansion Of The Antimicrobial Resistance Diagnostics Market?

The growing occurrence of drug-resistant infections is anticipated to drive the expansion of the antimicrobial resistance diagnostics market. These infections develop when bacteria, viruses, fungi, or parasites adapt ways to withstand medications that were once effective, rendering conventional treatments useless and infections more challenging to manage. The increasing spread of drug-resistant infections stems from the excessive use of antibiotics in agriculture, where low-dose antimicrobials are commonly incorporated into animal feed, fostering resistance that can transfer to humans via the food chain. Antimicrobial resistance diagnostics, including rapid genetic assays and culture-based sensitivity tests, are essential in combating the rising incidence of drug-resistant infections. They achieve this by allowing for prompt identification of resistant pathogens, directing precise treatments, and lessening the inappropriate use of broad-spectrum antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a UK-based government agency, stated that the count of serious antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023. Concurrently, antibiotic consumption rose by 2.4% in 2023 compared to 2022. Consequently, the escalating prevalence of drug-resistant infections is a key factor propelling the expansion of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Structured Across Different Segments?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Shaping The Future Of The Antimicrobial Resistance Diagnostics Market?

Companies operating in the **antimicrobial resistance (AMR) diagnostics market** are strategically using innovative technologies, such as **point-of-care antimicrobial-susceptibility testing (AST) technologies**, to enhance diagnostic speed, precision, and the effectiveness of antimicrobial stewardship programs. **Point-of-care antimicrobial-susceptibility testing (AST)** refers to quick tests conducted near the patient that determine which antibiotics are effective against an infection, enabling clinicians to rapidly choose targeted and effective treatments. For example, in **June 2023**, **Sysmex Corporation**, a Japan-based provider of in-vitro diagnostic solutions, launched the **PA-100 AST System**. This platform is a rapid, point-of-care AST system designed to detect bacterial presence and ascertain antimicrobial susceptibility in urine samples within approximately **30 minutes**. The system includes microfluidic single-cell analysis, near-patient testing capabilities, and automated reporting of susceptibility outcomes. The **PA-100 AST System** improves clinical decision-making, helps reduce unnecessary antibiotic prescriptions, and supports timely, targeted therapies to combat antimicrobial resistance.

Which Major Players Dominate The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Read the full antimicrobial resistance diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Antimicrobial Resistance Diagnostics Market?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antimicrobial Resistance Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cell therapy bioreactors market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Antimicrobial Resistance Diagnostics Market be in 2030 compared with 2026?

The size of the antimicrobial resistance diagnostics market has experienced robust growth over recent years. This market is projected to expand from $4.41 billion in 2025 to $4.74 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historically, this growth has been driven by factors such as the increasing spread of antibiotic-resistant infections, the widespread use of traditional culture-based diagnostic methods, an uptick in hospital-acquired infections, a heightened understanding of antimicrobial stewardship, and the proliferation of clinical microbiology laboratories.

The antimicrobial resistance diagnostics market is anticipated to experience substantial expansion over the coming years, reaching $6.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth is driven by several factors, including advancements in PCR and NGS diagnostic technologies, an increase in government funding allocated to AMR surveillance initiatives, the growing acceptance of rapid diagnostic tests, an expansion in pharmaceutical and biotechnology research, and the incorporation of data-driven decision support tools. Key trends shaping the forecast period involve a rising uptake of rapid and point-of-care antimicrobial resistance diagnostics, an increasing need for targeted and personalized antimicrobial treatments, enhanced monitoring of drug-resistant pathogens, the broadening of molecular and genomic diagnostic testing, and the reinforcement of hospital infection control and stewardship strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

What Drivers Are Guiding Growth Patterns In The Antimicrobial Resistance Diagnostics Market?

The increasing occurrence of drug-resistant infections is anticipated to boost the expansion of the antimicrobial resistance diagnostics market in the future. These infections develop when microbes such as bacteria, viruses, fungi, or parasites acquire ways to withstand drugs that previously worked, rendering conventional treatments useless and infections more challenging to manage. The expanding presence of drug-resistant infections stems from the excessive use of antibiotics in farming, where small amounts of antimicrobials are regularly incorporated into animal feed, fostering resistance capable of transmitting to humans via the food chain. Tools like rapid genetic assays and culture-based sensitivity tests within antimicrobial resistance diagnostics are crucial in countering the rising incidence of drug-resistant infections, as they facilitate prompt detection of resistant disease-causing agents, direct specific treatments, and decrease the inappropriate use of wide-ranging antibiotics. As an illustration, in November 2024, the UK Health Security Agency (UKHSA), a government body in the UK, stated that serious antibiotic-resistant infections in England climbed from 58,224 in 2022 to an estimated 66,730 in 2023, concurrently with antibiotic use growing to 2.4% in 2023 from 2022. Consequently, the increasing occurrence of drug-resistant infections is propelling the growth of the antimicrobial resistance diagnostics market.

How Is The Antimicrobial Resistance Diagnostics Market Divided Into Segments?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

Which Trends Are Influencing The Performance And Direction Of The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance (AMR) diagnostics market are increasingly leveraging innovative technologies, such as point-of-care antimicrobial-susceptibility testing (AST) solutions, to boost diagnostic speed, precision, and antimicrobial-stewardship outcomes. Point-of-care antimicrobial-susceptibility testing (AST) involves rapid, near-patient analyses that pinpoint which antibiotics will be effective against an infection, thereby assisting clinicians in quickly selecting targeted and successful treatments. For instance, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, launched its PA-100 AST System, a point-of-care rapid AST platform designed to detect bacterial presence and determine antimicrobial susceptibility in urine samples within approximately 30 minutes. This system incorporates features such as microfluidic single-cell analysis, near-patient testing capabilities, and automated reporting of susceptibility results. The PA-100 AST System thereby improves clinical decision-making, reduces unnecessary antibiotic prescriptions, and supports timely, targeted therapy to combat antimicrobial resistance.

Which Leading Companies Dominate The Antimicrobial Resistance Diagnostics Market Share?

Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

How Does The Antimicrobial Resistance Diagnostics Market Perform Across Major Global Regions?

North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antimicrobial Resistance Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2026, By The Business Research Company

Sleep Apnea Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Sleep Tech Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-tech-devices-global-market-report

Sinus Dilation Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinus-dilation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Antimicrobial Resistance Diagnostics Market?

The market size for antimicrobial resistance diagnostics has seen substantial growth in the past few years. The market is projected to expand from $4.10 billion in 2024 to $4.41 billion in 2025, registering a compound annual growth rate (CAGR) of 7.5%. Factors that have contributed to this growth in the past include a rise in hospital-acquired infections, inappropriate use of antibiotics in humans and animals, the growing prevalence of multidrug-resistant organisms, an increase in public health monitoring programs, and a surge in diagnostic testing for infectious diseases.

In the coming years, the antimicrobial resistance diagnostics market is projected to experience robust growth. Estimated to rise to $5.82 billion by 2029 with a compound annual growth rate (CAGR) of 7.2%, the growth during this forecast period can be linked to the increasing demand for swift diagnostic devices, heightened awareness on antimicrobial stewardship, escalating government support for resistance tracking, and the growing utilization of point-of-care testing. Noteworthy trends expected during this period encompass technological progression in diagnostic platforms, innovative techniques in resistance gene discovery, increased investment in research and development, creation of transportable testing equipment, and pioneering developments in multiplex and high-throughput testing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp

What Growth-Enabling Forces Are Impacting The Antimicrobial Resistance Diagnostics Market?

The growth of the antimicrobial resistance diagnostics market is anticipated to be fueled by the increasing occurrence of drug-resistant infections. Such infections, resistant to previously effective medications, evolve when bacteria, viruses, fungi, or parasites develop survival mechanisms making standard treatments useless and infections more challenging to control. The expansion of drug-resistant infections can be attributed to the excessive use of antibiotics in farming—low-dose antimicrobials are routinely included in animal feed, fostering resistance that can spread to humans via the food chain. Essential tools for battling the escalating occurrence of drug-resistant infections, antimicrobial resistance diagnostics like rapid genetic assays and culture-based sensitivity tests, help with the early detection of resistant pathogens, guide targeted therapies, and lower the misuse of broad-spectrum antibiotics. As an example, a UK Health Security Agency (UKHSA) report in November 2023 stated that antibiotic-resistant infections in England increased from 55,792 cases in 2021 to around 58,224 in 2022, indicative of a 4% annual increase in antimicrobial resistance across the country. Hence, the escalating occurrence of drug-resistant infections is fueling the growth of the antimicrobial resistance diagnostics market.

How Does The Antimicrobial Resistance Diagnostics Market Differ By Segment?

The antimicrobial resistance diagnostics market covered in this report is segmented –

1) By Product Type: Kits And Reagents, Instruments And Consumables

2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens

3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies

4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media

2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs

What New Opportunities Are Emerging From Trends In The Antimicrobial Resistance Diagnostics Market?

Leading corporations in the antimicrobial resistance diagnostics market are zeroing in on the production of innovative products like multiplex polymerase chain reaction (PCR) assays. These can detect multiple pathogens and resistance genes concurrently, improving both the efficacy and accuracy of diagnosis. Multiplex PCR consolidates several primer sets in one reaction to recognize various DNA targets simultaneously, which saves time and resources considerably. For example, Vela Diagnostics, a molecular diagnostics firm from Singapore, introduced the PathoKey MP urinary tract infections (UTI) ID and antimicrobial resistance (AMR) PCR Test in May 2022. This product allows for the concurrent detection of 14 UTI pathogens and 14 antimicrobial resistance genes. Plus, it supports both automated and manual workflows and can deliver results in just four hours, aiding quick, lab-scale AMR profiling. The PathoKey MP UTI ID & AMR PCR Test is aimed at equipping clinical laboratories with speedy, high-throughput detection abilities, facilitating early intervention and effective antibiotic treatment.

Who Are The Most Influential Companies In The Antimicrobial Resistance Diagnostics Market?

Major companies operating in the antimicrobial resistance diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Seegene Inc., Alifax S.r.l., Accelerate Diagnostics Inc., Lumos Diagnostics Holdings Pty Ltd, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc., OpGen Inc., T2 Biosystems, Jiangsu Medomics Medical Technology Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antimicrobial-resistance-diagnostics-global-market-report

Which Region Is Leading Innovation In The Antimicrobial Resistance Diagnostics Market?

North America was the largest region in the antimicrobial resistance diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp

Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model